A recent prospective study demonstrated genetic variations in eight genes, including BRAF, EGFR, and ERBB2 mutations, ALK, RET, and ROS1 rearrangements, MET amplifications and exon 14 skipping, were recommended as biomarkers via the Guardant360 test based on eight 70-gene NGS panels in metastatic NSCLC (10). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.